LAUSANNE, Switzerland, Nov. 25, 2019 /PRNewswire/ — Long battery life, precision of measurements and very small size are the key requirements for vital signs monitoring sensors in hearable devices.
Despite ultra small detector area (70dB SNR. In addition, the ActLight solution provides a very strong output signal without AFE, further reducing the power consumption of the overall system.
The Dynamic PhotoDiode is the vital signs monitoring sensor of choice to meet the very demanding technical requirements of the hearable devices market.
For more information, contact us at info@act-light.com
About ActLight: ActLight SA, the company founded in 2011 and based in Switzerland, focuses on CMOS photonics and licenses its IP to customers in this field.
The patented CMOS-based photonics technology allows the substantial improvement of the efficiency and accuracy of various light sensing applications, such as Time-Of-Flight (TOF) based range meters, vital signs monitoring, 3D/2D cameras and much more. ActLight operates in the Internet of Things (IoT) market, with a focus on mobile and wearable devices, healthcare/medtech, autonomous driving, drones and robotics.
Photo – https://healthtechnologynet.com/wp-content/uploads/2019/11/ActLight_Dynamic_PhotoDiode.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2019/11/ActLight_Logo.jpg
View original content to download multimedia:http://www.prnewswire.com/news-releases/actlight-ultra-small-very-low-power-consumption-heart-rate-monitoring-sensor-for-hearables-you-need-the-actlight-dynamic-photodiode-300964257.html
SOURCE ActLight
Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…